AVII - AVI BioPharma (Cancer Vaccine) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVII - AVI BioPharma (Cancer Vaccine)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	3/30/2007 12:52:25 PM
	of 284

AVII AVI BioPharma initiated with a Buy at Maxim- tgt $5 (2.41 ) Maxim initiates AVII with a Buy and a $5 tgt saying the valuation of AVII is driven by its technology know-how in developing 3rd generation antisense therapeutics against serious infectious diseases/bioterrorism agents, as well as "multiple shots on goal" clinical efforts in cardiovascular diseases, HCV, drug metabolism and genetic disorders. The firm believes that the current valuation of AVII is compelling and the downside risk is minimal. Firm notes various clinical milestones and potential partnership announcements expected over the next 9-12 months, as well as any future opportunistic pandemic or bioterrorism threats, could result in significant upside to the stock.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next